First Round

DEBATE
After the release of the first recommendation from the PRAC, two drug utilization studies found that HES solutions were frequently used on an off-label basis, with septic patients receiving the compound. These findings released a discussion that included an EMA ad-hoc expert meeting on December 18 th , 2017, when it was recommended to the PRAC to not suspend the commercialization of HES. The experts' opinion was based on different studies that were published after the initial recommendation of the PRAC. The first one was a large study conducted in intensive care patients, treatment of acute hypovolemia with colloids was not associated with increased 28 day mortality, and even better 90 day survival, as compared to crystalloids (5). Colloids were able to more effectively stabilize arterial blood pressure and were not associated with increased risk of acute kidney injury. The second one was a meta-analysis of 32 trials and including >16600 patients in total, which showed that colloids did not increase mortality in critically ill, surgery and trauma patients (6) . Furthermore, compared to crystalloids, colloids did not increase the risk of acute kidney insufficiency in surgery patients, and even decrease it in trauma patients. Despite this overwhelming body of evidence and the fact that two large multicenter trials were being conducted, as suggested by the EMA, the PRAC recommended on January 12 th , 2018, the suspension of HES from the European market, which was then approved by the CMDh two weeks thereafter. Since then, the discussion on the suspension of the market authorization has involved the European Commission, the PRAC and the CMDh, also with consultations with experts. Whether HES will be suspended is still unclear, but the steering committees of PHOENICS and TETHYS studies decided re-launching the trials. We fully support this decision.
It is important to highlight that the recommendation of the PRAC early in this year would not have affected the running studies. In a response letter addressed to the ESA, the EMA stated that any decision on the commercialization of HES would not interfere with the studies mentioned above. Despite this, a debate arose regarding ethical aspects of conducting clinical studies on a compound, whose authorization for commercialization was unclear. The conditions where HES was supposed to be tested, namely acute hypovolemia due to blood loss during abdominal surgery or trauma, are exactly the ones that have been recognized as favorable for this colloid. Furthermore, we are the opinion that the potential hazard of a premature withdrawal of the commercialization of HES can impact negatively on outcome of the target population. Alternative drugs, for example gelatins and dextrans, are associated with similar risks in terms of kidney functions (7), and carry others, for example anaphylactic reactions, which we, the authors, could unfortunately testimony several times, and tend stay less longer than crystalloids in the circulation (8) . The "more physiological" albumin containing solutions have a risk profile that is not fully understood, while their costs may pose a burden to health systems and lead to their shortage in the middle term. One could even argue that balanced crystalloids might be sufficient, but those compounds are also not free of hazardous effects.
Since HES is prescribed and administered solely by physicians, instead of withdrawing a drug from the market due to inappropriate use, it makes more sense to raise the awareness of the medical personnel to the indications and contraindications of the product. This can be easily achieved by, for example, changes in labeling of the compound, educational material, possible the use of checklists, and by controlled delivery of HES from the hospital pharmacy to the operation and emergency theaters only, which would avoid its inadvertent use in intensive care units. Obviously, re-assessment of utilization must be conducted after those measures have been implemented and adapted as needed. Whatever the final decision from the EMA may be, stopping running trials that may give a definitive answer to the safety of the compound under appropriate indications is unconceivable, while the suspension of the commercialization of HES is also potentially hazardous. The best way for farmers to get rid of ticks is certainly not by killing the cow.
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